These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of LRRK2 in the regulation of dopamine receptor trafficking. Rassu M; Del Giudice MG; Sanna S; Taymans JM; Morari M; Brugnoli A; Frassineti M; Masala A; Esposito S; Galioto M; Valle C; Carri MT; Biosa A; Greggio E; Crosio C; Iaccarino C PLoS One; 2017; 12(6):e0179082. PubMed ID: 28582422 [TBL] [Abstract][Full Text] [Related]
3. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001 [TBL] [Abstract][Full Text] [Related]
4. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. Dusonchet J; Kochubey O; Stafa K; Young SM; Zufferey R; Moore DJ; Schneider BL; Aebischer P J Neurosci; 2011 Jan; 31(3):907-12. PubMed ID: 21248115 [TBL] [Abstract][Full Text] [Related]
5. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation. Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589 [TBL] [Abstract][Full Text] [Related]
6. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons. Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882 [TBL] [Abstract][Full Text] [Related]
7. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A. Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905 [TBL] [Abstract][Full Text] [Related]
8. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation. Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895 [TBL] [Abstract][Full Text] [Related]
9. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188 [TBL] [Abstract][Full Text] [Related]
10. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
11. LRRK2 and vesicle trafficking. Sanna G; Del Giudice MG; Crosio C; Iaccarino C Biochem Soc Trans; 2012 Oct; 40(5):1117-22. PubMed ID: 22988875 [TBL] [Abstract][Full Text] [Related]
15. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Greggio E Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865 [TBL] [Abstract][Full Text] [Related]
16. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998 [TBL] [Abstract][Full Text] [Related]
17. Parkinson's-linked LRRK2-G2019S derails AMPAR trafficking, mobility, and composition in striatum with cell-type and subunit specificity. Gupta S; Tielemans A; Guevara CA; Huntley GW; Benson DL Proc Natl Acad Sci U S A; 2024 Jul; 121(28):e2317833121. PubMed ID: 38968112 [TBL] [Abstract][Full Text] [Related]
18. Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2. Belluzzi E; Greggio E; Piccoli G Biochem Soc Trans; 2012 Oct; 40(5):1111-6. PubMed ID: 22988874 [TBL] [Abstract][Full Text] [Related]
19. Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype. Rassu M; Biosa A; Galioto M; Fais M; Sini P; Greggio E; Piccoli G; Crosio C; Iaccarino C J Cell Mol Med; 2019 Dec; 23(12):8505-8510. PubMed ID: 31560168 [TBL] [Abstract][Full Text] [Related]
20. Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Martin I; Kim JW; Lee BD; Kang HC; Xu JC; Jia H; Stankowski J; Kim MS; Zhong J; Kumar M; Andrabi SA; Xiong Y; Dickson DW; Wszolek ZK; Pandey A; Dawson TM; Dawson VL Cell; 2014 Apr; 157(2):472-485. PubMed ID: 24725412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]